Research programme: second generation T cell receptor therapeutics - Kite Pharma/bluebird bio

Drug Profile

Research programme: second generation T cell receptor therapeutics - Kite Pharma/bluebird bio

Alternative Names: Second generation HPV-16 E6 TCR - Kite/bluebird bio; Second generation TCR therapeutics - Kite Pharma/bluebird bio

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator bluebird bio; Kite Pharma
  • Developer Kite Pharma
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E6 T cell receptor expression modulators; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 06 Apr 2017 Preclinical development of second generation HPV-16 E6 TCR for HPV-associated Cancers is ongoing in USA (Parenteral)
  • 22 Jun 2015 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top